Immediate Impact
52 standout
Citing Papers
The hallmarks of cancer immune evasion
2024 Standout
Advances in diagnosis and management of cancer of the esophagus
2024 Standout
Works of M. Polée being referenced
A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study
2012
Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy
2003
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| M. Polée | 214 | 190 | 114 | 13 | 327 | |
| Antonio Manganelli | 174 | 145 | 94 | 15 | 322 | |
| Yoichi Saitoh | 80 | 198 | 155 | 14 | 328 | |
| Kyriakos Zafirellis | 166 | 215 | 69 | 9 | 321 | |
| G Tripsianis | 185 | 152 | 149 | 14 | 369 | |
| Shuai Hu | 119 | 73 | 80 | 16 | 293 | |
| Xianfa Wang | 180 | 98 | 253 | 13 | 371 | |
| Kazuya Kuwada | 122 | 123 | 122 | 20 | 356 | |
| Suraj Alva | 67 | 151 | 98 | 14 | 269 | |
| P. J. Cagnoni | 88 | 55 | 147 | 15 | 293 | |
| Gerard A. Croll | 90 | 141 | 113 | 9 | 354 |
All Works
Loading papers...